Sana director granted 90,000 stock options

Sana Biotechnology, Inc. director Joshua H. Bilenker received a grant of stock options covering 90,000 shares of common stock.

Rhea-AI Filing Summary

Sana Biotechnology, Inc. director Joshua H. Bilenker received a grant of stock options covering 90,000 shares of common stock. The options have an exercise price of $2.9600 per share and expire on June 3, 2036.

These options vest and become exercisable in full on the earlier of June 4, 2027 or immediately before Sana’s 2027 annual meeting of stockholders, provided he continues to serve the company through that date. Following this grant, he holds 90,000 derivative securities directly.

Insider Trade Summary

Grant/Award: 90,000 shares

Grant/Award 1 txn

Insider Bilenker Joshua H.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	90,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 90,000 contracts (Direct)

Footnotes (1)

1. F1. The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

Key Figures

Options granted: 90,000 options Exercise price: $2.9600 per share Underlying shares: 90,000 shares +3 more

6 metrics

Options granted 90,000 options Stock Option (Right to Buy) granted to director

Exercise price $2.9600 per share Exercise price of granted stock options

Underlying shares 90,000 shares Common stock underlying the options

Expiration date June 3, 2036 Option expiration

Vesting date trigger June 4, 2027 or 2027 meeting Earlier of date or 2027 annual meeting, continuous service required

Post-grant holdings 90,000 derivative securities Total options held directly after this grant

Key Terms

Stock Option (Right to Buy), exercise price, vests and becomes exercisable, annual meeting of stockholders, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "2.9600""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests and becomes exercisable financial

"The option vests and becomes exercisable as to 100% of the underlying shares"

annual meeting of stockholders financial

"immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc."

continuous service financial

"provided that the reporting person provides continuous service to Sana through such date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Joshua H. Bilenker receive in this Sana (SANA) Form 4 filing?

Joshua H. Bilenker received a grant of stock options for 90,000 shares of Sana common stock. These options are a form of equity compensation, allowing him to buy shares at a fixed exercise price if vesting conditions are met.

What is the exercise price of the options granted to Joshua H. Bilenker at Sana (SANA)?

The stock options have an exercise price of $2.9600 per share. This means Bilenker can purchase Sana common stock at this fixed price once the options vest and become exercisable, regardless of the future market price at that time.

When do Joshua H. Bilenker’s Sana (SANA) stock options vest?

The options vest and become exercisable for 100% of the 90,000 shares on the earlier of June 4, 2027, or immediately before Sana’s 2027 annual stockholder meeting, assuming Bilenker continues providing service to the company through that vesting date.

How long do the newly granted Sana (SANA) options remain exercisable?

The options expire on June 3, 2036, giving Bilenker a long window to exercise them after they vest. After the expiration date, any unexercised options will lapse and no longer provide the right to purchase Sana common shares.

How many Sana (SANA) derivative securities does Joshua H. Bilenker hold after this grant?

Following this grant, Bilenker holds 90,000 derivative securities related to Sana common stock. These represent the stock options reported in the filing, held directly in his name, subject to vesting and the stated exercise and expiration terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 04:32 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bilenker Joshua H.

(Last) (First) (Middle)

C/O SANA BIOTECHNOLOGY, INC.

188 EAST BLAINE STREET, SUITE 350

(Street)

SEATTLE WASHINGTON 98102

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sana Biotechnology, Inc. [ SANA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.96	06/04/2026		A		90,000		(1)	06/03/2036	Common Stock	90,000	$0.00	90,000	D

Explanation of Responses:

1. The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

Remarks:

Exhibit List: Ex. 24 - Power of Attorney

	/s/ Aaron M. Grossman, Attorney-in-Fact for Joshua H. Bilenker	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)